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The methods to study proteins are continuously improving, making it
possible to identify and study increasingly more proteins. It is import-
ant to keep studying and improving the way experiments are designed,
performed, and interpreted. This thesis concerns statistical considera-
tions for the design and interpretation of proteomics experiments using
mass spectrometry. Mainly the focus is on protein and pathway inter-
actions and networks, extending an existing workflow to additionally
identify very small peptides and single amino acids, and effectively
making balanced batches in a fixed cohort.
The biological functions of proteins are determined by their interac-
tions with other molecules. While most proteins have a limited number
of specific interaction partners, the whole system of these interactions
is part of what defines organisms. Interactions between proteins, and
with other molecules, can be grouped in different types of reactions. A
set of actions and reactions leading to a specific outcome is a pathway,
which defines a, more or less specific, process. Results from statistical
analyses of protein abundances are often put in a biological context by
way of mapping proteins to these pathways, i.e. by pathway analysis.
The interactions between proteins and the definitions of pathways
are collected in pathway databases, based on available literature or
computational inference. Due to the central role these databases play
in the interpretation of proteomics experiments, they can directly in-
fluence the outcome of pathway analysis algorithms. We investigated
the structure and evolution of one of the manually curated pathway
databases, by using network statistics focusing on the connectivity of
the annotated proteins and the hierarchical nature of the pathways.
Additionally, we hope to aid in improving the understanding of the
underlying basis for pathway analysis results and give practical advice
for their interpretation.
Several pathways involve the digestion of proteins. This is done not
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only to extract energy from food, but also in order to modify proteins
by proteolytic cleavage or to recycle proteins so their amino acids can
be reused in other proteins. Additionally, small peptides and single
amino acids can have functions of their own and play an important
role in maintaining homeostasis. Differential abundance of endogenous
(i.e. naturally occurring) peptides can thus potentially be used as an
indication of possible dysfunctional proteases, peptidases, or proteolytic
pathways.
Using mass spectrometry only molecules that can attract a charge
will be possible to detect. Many amino acids and very small peptides
are not able to attract a charge under standard conditions in mass spec-
trometry. Additionally, singly charged molecules are often ignored as
they are likely to be contamination. While there are kits to specifically
detect single amino acids and some small peptides using mass spectro-
metry, these are not easily incorporated into standard workflows. In a
proof-of-concept experiment we used isobaric tags in a standard pep-
tidomics workflow. As the tags acquire a charge themselves, this makes
it possible to detect the single amino acids and very small peptides
when singly charged molecules are also selected for fragmentation. The
identification of the isobaric tag in the MS2 spectra serves as a rudi-
mentary check that the molecule is not a contaminant. This simple
addition to a standard workflow, combined with a naive mass-based
identification approach, showed that with a limited amount of extra
work a large amount of single amino acids and small endogenous pep-
tides could be identified, which could lead to potential novel insights
and understanding.
Processing of samples in biomedical experiments generally proceeds
sequentially. Due to time and technical limitations, the number of
samples that can be processed at once is often limited to less than
the number of available samples, which means that at least some steps
of the experiment will have to be processed in different batches. It then
becomes important to make sure that the batching process does not
introduce confounders. For smaller experiments this is feasible to do
by hand for expert scientists, but quickly becomes cumbersome and
time-consuming for large and imbalanced cohort set-ups.
To aid in the process of designing batch allocations that are as bal-
anced as possible, given the available samples, we have developed a
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fast and intuitive heuristic algorithm, which can be applied to single-
variable model where the treatment variable is nominal. This auto-
mated procedure can free researchers to focus on other aspects of the
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1 Proteomics
This thesis concerns statistical considerations when designing proteo-
mics experiments using mass spectrometry. First, a short introduction
to the main biological concepts important for the included papers will
be provided.
1.1 Proteins
Living cellular organisms share the same fundamental building blocks
and machinery for basic functions. Some species consist of a single cell,
e.g. bacteria, while others consist of many cells, e.g. humans consist of
more than 1013 cells, though start out as a single cell (Alberts et al.,
2015). The largest constituent of a cell, after water, is the proteins, the
molecules that are responsible for most of the biochemical activity. For
example, enzymes are proteins with catalytic activity, while other pro-
teins function as signal receptors, transporters, or structural elements.
Proteins perform their functions by interacting with other proteins and
other molecules. The proteins that make up the functioning of these
systems are essential for a better understanding of the processes in the
cell, and the diversity between cells and organisms (Twyman, 2014).
The proteins themselves are built up from amino acids, of which 20
are directly coded for in the genetic material (Table 1.1). Each amino
acid consists of a carbon atom with a hydrogen atom, a carboxyl group
(the C-terminal), an amino group (the N-terminal), and a side chain
(Figure 1.1). The side chain defines the amino acid (Alberts et al.,
2015; Nelson and Cox, 2017). When two or more amino acids bind to
each other, they form a peptide. In this process the N-terminal of one
amino acid connects to the C-terminal of the other amino acid, and
a molecule of water is released (Figure 1.2). A peptide consisting of
two amino acids is also called a dipeptide, tripeptides consist of three


















Figure 1.1: Basic structure of amino acids. Each amino acid consists of an
α-carbon with a hydrogen atom, an amino group (H2N), a carboxyl group and



















Figure 1.2: Peptide bond. When an amino acid is added to another amino
acid (or a chain of amino acids), the N-terminal of the new amino acid connects
to the C-terminal of the amino acid (chain). In this process one water molecule
is released.
acids is called a polypeptide, or a polypeptide chain, which mass can be
calculated as the sum of the residual masses of the constituent amino
acids plus a water molecule. A protein consists of one or more such
polypeptide chains.
Proteins are translated from ribonucleic acid (RNA), which itself is
transcribed from deoxyribonucleic acid (DNA) (Alberts et al., 2015).
Going from DNA (the genome) to RNA (transcriptome) to proteins
(proteome) from an omics point of view, each step is an order of mag-
nitude more complex. There are roughly 2 × 104 human genes, which
are transcribed into about 105 transcripts. The translation of an mRNA
transcript gives the amino acid sequence of a protein, which is the base






















































































































































































































































































































































































































































































































































































































































































properties of the amino acids, the polypeptide chain folds itself into
a particular shape (conformation), partly defined by the interactions
between the amino acids themselves, and also due to the interaction
between hydrophobic and hydrophilic amino acids and their surround-
ings.
The main function of a protein is defined by the order of its con-
stituent amino acids (Alberts et al., 2015). Each protein can have many
different forms, called proteoforms, which can each have different func-
tions. The different proteoforms can arise in the process of producing
the protein from DNA, i.e. when transcribing DNA to RNA, by al-
ternative splicing, or when translating mRNA into a polypeptide, or
after the protein has been produced. The latter modifications are called
post-translational modifications (PTMs). Common modifications are
changes to a standard amino acid, e.g. oxidation, methylation, or glyc-
osylation. A different type of modification is where part of the protein
is cut-off. These can lead to a different conformation, switch proteins
on or off, and change the function of the protein. Proteins can have
multiple PTMs at the same time, and in different combinations, with
the total number of proteoforms in a cell being on the order of 106
(Aebersold et al., 2018; Eidhammer et al., 2013).
The biological functions of a protein are determined by its inter-
actions with other molecules, e.g. antibodies interact with viruses or
bacteria, and other proteins interact with small molecules. Similarly,
when a protein binds to other proteins, they form a protein complex.
While the type of interactions and the interaction partners of proteins
can vary widely, the interactions of a specific protein are usually limited
to a small set of specific interaction partners (Alberts et al., 2015). The
(inter)actions of proteins are part of a large system trying to maintain
homeostasis. Series of actions/reactions within a specified system, or
with a specified goal, are called pathways (Jassal et al., 2020; Kanehisa
et al., 2016).
As a pathway can be defined as a set of actions/reactions leading to
a specific outcome, the smallest pathways can be defined as a single
reaction. These pathways can be connected to other pathways, which
generate its inputs or use its outputs. Together these pathways may
then form a larger, more general pathway. The largest pathways, e.g
the immune system, are very general and contain different sub-systems
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that might work independent of each other. Still, all analytes relate to
all other analytes and a perturbance in one part of the system can have
consequences in other parts of the system by following the paths of the
reactions ‘downstream’, so-called pathway cascades (e.g., Benchoula
et al., 2021; Katoh and Katoh, 2007).
1.2 Proteomics and peptidomics
All proteins together form the proteome, and the systematic character-
isation of the proteome, under a specific set of conditions, is called pro-
teomics (Nelson and Cox, 2017). This undertaking can be approached
from different, complementary angles. The most basic aspect of the
proteome is the examination of the constituent proteins. This can be
charting all proteins that exist in a species, but also more narrowly the
proteins present in e.g. a specific cell type, tissue section, body fluid,
or cell compartment. When proteins are identified, another aspect of
the proteome is the characterisation of the properties of the differ-
ent proteins. This can range from defining the amino acid sequence
and associated PTMs, to estimate protein abundances, identifying the
three-dimensional structure, and finding interaction partners in species
and cellular components. A different aspect of the proteome, once the
proteins in a sample are identified, is the quantification of the detected
proteins.
Very small proteins and naturally occurring shorter amino acid chains
can also have specific roles in the cell, e.g. cytokines, or antimicrobial
agents, however, such bioactive peptides can usually not be predicted
from the genome (Schrader, 2018). Other peptides are products of lar-
ger proteins, the result of (specific or unspecific) proteolytic degrad-
ation. Note that there is no clear distinction between proteins and
peptides, but when a distinction is made it is usually with a size or
weight cut-off around 10–15 kDa. The endogenous peptides present in
a sample are referred to as the peptidome, the study of which is called
peptidomics.
A standard part of proteomics protocols, for reasons that will be
explained in Chapter 2, is to cut the proteins into smaller peptides be-
fore analysing them. First, proteins are denatured, turning them into
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unfolded polypeptide chains that a protease can subsequently cut into
smaller peptides. With a highly specific protease, the obtained peptides
can be predicted from the protein amino acid sequence. Trypsin, the
most used protease for proteomics studies, cuts after arginine and lys-
ine, unless followed by proline. Both arginine and lysine are common
amino acids, so each protein is cleaved into many small pieces suitable
for mass spectrometry analysis (Vandermarliere et al., 2013).
1.3 Biomarkers
The goal of biomedical experiments is often to gain insight into how
biological processes work, or are altered by interventions or diseases.
One way of doing this is to search for indications in the body that can
tell us the state of the organism. These indications are called biomarkers
and are defined by Biomarkers Definitions Working Group (2001) as
A characteristic that is objectively measured and evaluated
as an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to a therapeutic in-
tervention (p. 91)
As a simple example, body temperature gives an indication of fever.
Similarly, there are biomarkers used to diagnose rheumatoid arthritis
which can be detected by adding specific antibodies to blood samples
(Rose et al., 1948).
The development of a biomarker is a long process, requiring devel-
opment steps in both research and clinical settings (Simon, 2008). One
way of classifying biomarkers is by their intended use: (i) diagnostic
biomarkers are used to diagnose, or rule out, a certain disease, (ii) pro-
gnostic biomarkers are used to predict how a disease would progress
with or without treatment, and (iii) predictive biomarkers are used to
differentiate between those benefiting from an intervention and those
who would not. Predictive biomarkers are especially relevant for can-
cer treatments, as those are often toxic, expensive, and only marginally
effective (Ankeny et al., 2018; Janes et al., 2015).
The four performance metrics commonly used to assess biomarkers
are sensitivity, specificity, positive predictive values (PPV), and negat-
ive predictive values (NPV) (Simon, 2015). These are easiest to define
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for diagnostic markers, though can be defined analogously for the other
markers. PPV is the probability that the subject has the disease given
a positive marker, while NPV is the opposite: the probability that the
subject does not have the disease given a negative marker. Sensitiv-
ity is the probability that the marker is positive for subjects with the
disease, and, similarly, specificity is the probability that the marker is
negative for subjects who do not have the disease. Thus, when a sub-
ject receives a positive result on a diagnostic biomarker, this does not
necessarily mean that the person definitely has the disease. Instead,
basing calculations solely on the result from the biomarker, it is pos-
sible to calculate the probability of having the disease, given a positive
test on the marker with Bayes’ formula as (Gelman et al., 2013)
P (disease|marker = true) =
P (marker = true|disease)× P (disease)
P (marker = true)
(1.1)
where P (marker = true|disease) is the sensitivity of the test, and
P (disease) the disease prevalence. P (marker = true) is the probabil-
ity of getting a positive result on the biomarker, which can happen in
two ways: either when having the disease (sensitivity×prevalence), or
when not having the disease ((1 − specificity)×(1− prevalence)), thus
P (marker = true) = (sensitivity × prevalence) + (1− specificity)×
(1− prevalence). In reality, there will usually be more indications of
possibly having the disease, which should be weighed along with the
evidence from the biomarker. Additionally, multiple biomarkers can
be used in a panel, to strengthen the sensitivity, or to rule out dis-
eases with similar characteristics. Although in those cases, correlations
between different markers should be taken into account.
Some disease-specific genetic biomarkers are known, e.g. for breast
cancer the oestrogen and progesterone receptors and the human epi-
dermal growth factor receptor 1, which can be measured at gene, tran-
script, or proteome level. The search for novel biomarkers using omics
platforms, however, still faces several challenges (Nicolini et al., 2018).
For example, many markers based on multiple genes/proteins are not
reproducible in other datasets, or with different platforms, and suffer
from instability when reprocessed on the same dataset (Begley and
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Ioannidis, 2015; Goh and Wong, 2016b; Venet et al., 2011; Wang et al.,
2017).
1.4 Diversity of the proteome
Compared to the genome, the proteome shows dramatically more vari-
ability over the course of a day and over the course of a lifetime (Plumel
et al., 2019; Robin et al., 2020; Robles et al., 2014; Tsuji et al., 2007;
Wang et al., 2018). Monogenic diseases are easy to find when it is known
what to look for (e.g. maturity onset diabetes of the young (McDonald
and Ellard, 2013), cystic fibrosis (O’Sullivan and Freedman, 2009), hae-
mophilia A and B (Dolan et al., 2018)), though the consequences are
visible as non- or dis-functioning proteins. More complex diseases that
do not have a single genetic component might be possible (or easier)
to understand in terms of protein regulations (Zaghlool et al., 2021).
The diversity of the proteome manifests itself at several levels. Firstly,
proteins can exist in multiple different proteoforms. Secondly, proteins
can be present in different proportions or abundances, as they are af-
fected by processes inside and outside the body. Finally, some proteins
exist in some species or cell-types but not in others, as evidenced by
e.g. species specific databases (The UniProt Consortium, 2019) and the
human protein atlas (Uhlén et al., 2015). This high variability of the
proteome poses major challenges in terms of data analysis. Changes
in protein abundance can arise due to differential regulation due to,
e.g., disease state, but can also come from inherent differences between
subjects, or subtle, unknown biases in sample collection. Disease-driven
changes of the proteome thus have to be larger than the inherent vari-
ability between the subjects, and/or have to be known in advance and
targeted specifically.
Different body fluids and tissues also have different characteristics.
For example, blood, brain, liver, and cerebrospinal fluid (CSF) have
different properties and functions, and thus a different proteome. To
be able to properly analyse the different sample types, the differences
need to be accounted for in sample preparation and data analysis. For
example, in blood, the protein serum albumin is so abundant that it
dwarfs the abundance of other proteins (Pietrowska et al., 2019; To-
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mascova et al., 2019). Furthermore, platelet proteomics is special in
the sense that platelets do not have a nucleus (Smith et al., 2013), but
display different behaviour depending on their surroundings (Clemet-
son and Clemetson, 2013). Another interesting example is urine, for
both proteomics and metabolomics, as it is one of the easiest accessible
sources of waste-products of bodily processes (Palanski et al., 2021; Wu
and Gao, 2015).
A body fluid that is especially relevant for this thesis is CSF. It con-
tains waste-products of brain processes, and is thus potentially very in-
teresting for the investigation of neurological disorders (Hansson et al.,
2017). The CSF proteome contains both proteins produced in the cent-
ral nervous system, used by the brain, and also proteins that have
breached the blood-brain barrier. In addition, it is one of the places
where proteins are broken down into smaller peptides and single amino
acids, for reuse by the body. Both the proteome and the peptidome can
give complementary indications concerning the state of the organism,




The analysis of the protein/peptide samples is done on specialised in-
strumentation. Mass spectrometry (MS), coupled to liquid chromato-
graphy (LC) is the most common method used for the identification
and quantification of the proteins (or peptides) present in a sample, by
measuring the mass to charge ratio of proteins/peptides. Here follows
a short introduction to the instrumentation and techniques relevant to
the papers included in this thesis.
2.1 Instrumentation
The most common way to identify and quantify proteins in a sample
is by liquid chromatography coupled to mass spectrometry (LC-MS).
A mass spectrometer is in its essence a large, very precise scale for
measuring small charged molecules. In its simplest representation, a
mass spectrometer consists of three elements: an ionisation source, a
mass analyser, and an ion detector. To reduce the number of particles
entering the mass spectrometer simultaneously, the sample content is
first separated by liquid chromatography (LC), which feeds directly
into the mass spectrometer’s ionisation source.
This section mainly relies on the mass spectrometry textbook from
Gross (2017), which, for ease of reading, will not be cited after every
paragraph. Where additional information is taken from other sources,
these are cited specifically.
2.1.1 Liquid Chromatography
Liquid chromatography consists of a solid and a mobile phase, sorting
the molecules in the sample based on their differences in interaction
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with the two phases. The most common type of chromatography used
in mass spectrometry is reverse phase high-performance liquid chroma-
tography (HPLC), which separates molecules based on hydrophobicity
(Twyman, 2014). Beads with hydrophobic ligands, packed in a column,
form the stationary phase. The mobile phase, a polar solvent contain-
ing the dissolved sample, is loaded onto the column entirely and forced
under pressure through the solid phase. Molecules in the sample in-
teract with both the solid and the mobile phase, such that molecules
with a certain hydrophobicity stick to the solid phase, while other mo-
lecules stay in the liquid phase and are carried through. The interaction
between the molecules and the solid phase is regulated by the concentra-
tion of an organic modifier in the elution buffer, controlling the strength
with which molecules are adsorbed by the solid phase. By gradually in-
creasing this concentration, an increasing amount of molecules can pass
through the column, such that the weakest hydrophobic interactions are
released first. In addition, retention in the column tends to increase with
molecular mass, resulting in an additional mass-dependent separation.
2.1.2 Ionisation
Next, the sample has to be made available to the mass spectrometer
by ionising the molecules. The two most common ways of ionising bio-
molecules are matrix-assisted laser desorption/ionisation (MALDI) and
electrospray ionisation (ESI). In MALDI, the sample is smeared over
a metal plate and mixed with a matrix. A laser pulse irradiates part
of the sample, vaporising it and ionising the molecules, which can then
be accellerated into the mass spectrometer by an electric field. This
method produces mainly singly charged ions. ESI on the other hand
can be directly coupled to the HPLC system, injecting the molecules
that come out of the HPLC system into the ioniser through a capillary,
resulting in a fine spray of charged droplets. As the solvent evaporates,
the droplets shrink and are eventually ripped apart until only charged
molecules remain. This ionisation method produces molecules with a
stochastic number of ions/charges, which are subsequently guided into
the high vacuum chamber of the mass spectrometer by an electric field.
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2.1.3 Mass analysers
Mass analysers select ions based on their mass over charge ratio (m/z ).
The simplest mass analysers are linear quadrupole mass analysers,
which consist of four rod electrodes, placed in a square configuration,
in line with the direction of the ions. Two rods at opposite sides form a
pair, and the two pairs of rods are held at the same potential but with
opposite polarity. Molecules passing through the mass analyser oscil-
late between the rods according to their m/z and the potential applied
to the electrodes. Thus, by changing the potential, one can select the
range of m/z which will have a stable trajectory, i.e. will pass through
the mass analyser without hitting a rod or escaping through the gaps.
By placing electrodes with slightly higher potential than the rod
electrodes at the in- and the outlet of the quadrupole, a linear ion
trap is created. Setting the voltage at zero at the inlet and higher than
the rod electrodes at the outlet lets molecules into the quadrupole.
After the molecules have entered the mass analyser the inlet can be
closed again, by applying the same voltage as at the outlet, before the
smallest and fastest molecules can escape, thus trapping the ions. By
lowering the voltage at the outlet to something in between the voltage
of the rod electrodes and the inlet electrode, molecules are pushed out
of the quadrupole through the outlet. The quadrupole ion trap has,
in contrast to the linear quadrupole mass analyser, two hyperbolically
shaped electrodes as end caps and a ring electrode replacing two of the
linear quadrupole rods, resulting in an electrical field in three instead
of only two dimensions.
2.1.4 Detectors
After the selection of molecules, the next step is to detect which, and
how many, molecules are present. The conceptually simplest mass de-
tector is the time-of-flight (TOF) device, with the main principle being
that, when accelerated in an electric field, molecules with a higher m/z
take longer to fly a certain distance than molecules with a lower m/z .
By feeding the molecules at the same time into the TOF at a right
angle to the direction of flight, all molecules start at the same time and
with the same velocity. Recording the time it takes the molecules to
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fly through the whole tube, allows their m/z to be calculated. Longer
flight paths increase the difference in time it takes two molecules of
different m/z to reach the detector, thus increasing the resolution of
the instrument.
A different approach is taken by the Orbitrap, which is both a mass
analyser and ion trap, as well as a detector. It consists of an inner elec-
trode in the shape of a wire with a double-cone/spherical shaped bulge,
surrounded by an outer electrode. An electric field is applied between
the electrodes, such that molecules fly in a stable orbit around the inner
electrode. Due to the shape of the inner electrode, the molecules also
fly from one end of the sphere of the inner electrode to the other with a
stable frequency depending on the m/z . By splitting the outer electrode
into two parts, at the widest part of the inner electrode, the frequencies
of the oscillations of all molecules in the trap can be recorded. The m/z
and abundances of the molecules can then be calculated and deconvo-
luted by Fourier transform. To work properly, the molecules must be
fed into the Orbitrap at a specific angle, which is usually achieved with
a specially (C-)shaped quadrupole, called a C-trap.
2.1.5 Quality control
To monitor the stability of the instrument, quality control samples
should be run on a regular basis. In a recent review three types of qual-
ity control samples were identified: (i) single protein samples, (ii) cell
lysates, and (iii) synthetic peptides (Bittremieux et al., 2018). Single
protein samples are cheap and take a relatively small amount of time
to analyse, so they can be run often in between experimental samples.
These are generally used to quickly assess LC performance, by monitor-
ing the retention time and peak width. Cell lysates are more complex
samples, which more closely mimic experimental samples, making it
possible to monitor mass spectrometer performance. Typically small
amounts of quality control samples are injected, to monitor perform-
ance at low abundances. Samples containing synthetic peptides can
consist of as many (or few) different peptides as required. As the exact
peptide composition is known, these can be used to monitor perform-
ance for targeted approaches, and can even be added to experimental
samples. For all quality control samples it is important to avoid cross-
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contamination of experimental samples, e.g. by using (lysates contain-
ing) peptides that do not occur in the experimental samples.
The type of quality control sample defines what quality control met-
rics can be computed. In another recent review several types of quality
control metrics were identified (Bittremieux et al., 2017). Firstly, qual-
ity control metrics can be calculated for a specific experiment, or to
compare different experiments. Intra-experiment metrics indicate how
the instrument behaves over the course of a single experiment. These
can be, e.g. the mass accuracy of identified spectra, or the evolution
of the total ion current, which can show whether something unforeseen
happened in a specific run. Inter-experiment metrics, on the other hand,
summarise the quality of an experiment in a single number to compare
multiple experiments to each other, e.g. to assess the performance of
the mass spectrometer over time, which allows to compare runs to each
other and can indicate whether conditions between runs have changed.
Secondly, a distinction can be made between metrics derived dir-
ectly from the raw spectra, or metrics combining the raw spectra with
identification results. Identification-free metrics, based only on the raw
spectra, assess the whole MS workflow, e.g. number of spectra, or scan
rate. Identification-based methods combine the information from raw
spectra with identifications, and are thus also dependent on the qual-
ity of the identifications. However, as they use more information, these
metrics can provide more detailed quality assessments, e.g. sequence
coverage for a known sample, or number of identifications of peptides
and proteins. Lastly, instrument metrics provide low-level information
on different parts of the mass spectrometer. These are not directly re-
lated to experimental results, but are important for maintenance.
The type of quality control metric clearly depends on the quality
control samples (Bittremieux et al., 2017). For samples containing a
single protein digest, it is reasonable to expect the sequence coverage
to be stable across runs, while, as there is only a single protein in the
digest, the number of identifications is less relevant. In complex quality
control samples the identifications themselves may be less interesting
due to random fluctuations, and thus the number of identifications may
become more relevant than sequence coverage. Similarly, for discovery
experiments the number of identifications is relevant, while for targeted
experiments sequence coverage is more appropriate.
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Table 2.1: Elements and stable isotopes occurring naturally in proteins
(de Laeter et al., 2003).




















As the mass measurements are done at the scale of m/z , the observed
m/z values have to be transformed back into mass measurements. The
isotopic distributions of elements can help with this. The chemical ele-
ments making up amino acids exist in variants, called isotopes, which
have different numbers of neutrons. Apart from the radioactive iso-
topes, which are outside the scope of this thesis, these are biologically
indistinguishable, but, as shown in Table 2.1, have slightly different
masses and naturally occur in different abundances. The distribution
of the elemental masses (and thus of amino acids, peptides, and pro-
teins), is called the isotopic distribution, and can be used to identify
charge states and chemical composition.










































Figure 2.1: Isotopic distribution of a small peptide: MTDTVFSNSSNR. The blue



















































































Figure 2.2: Isotopic distribution of a larger peptide:
PQPMPIKKTKPQQPVSEPAAPEQPAPEPKHPAR. The blue bars represent the
monoisotopic peak for each charge state. (a) Peptide with a single charge.
(b) Peptide with two charges.
est isotopes is called the monoisotopic mass. Similarly, the peak of a
peptide consisting only of elements of the lightest isotopes is called the
monoisotopic peak. For small peptides this is also the highest peak, cor-
responding to the most abundant version of the peptide (Figure 2.1).
However, the more copies of an element that are present in the pep-
tide, the smaller the chance that they are all of the lightest isotope,
e.g. the chance that a single oxygen atoms is monoisotopic, is 0.9976,
while the chance that out of 100 oxygen atoms all are monoisotopic
is 0.9976100 = 0.7864. The distance between the isotopic peaks are
roughly one for ions with a single charge, 0.5 for ions with two charges
(Figure 2.2), and so on.
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2.1.7 Tandem MS
When intact peptides are measured, the only available information is
the m/z , the isotopic distribution, and, in case of LC-MS, the retention
time or elution time through the column. From these measurements it
is, unfortunately, not possible to obtain information about the amino
acid sequence, given that multiple sequences can have the same m/z ,
amongst which peptides with the same amino acids in a different or-
der. To get information about the amino acid sequence, tandem mass
spectrometry (also referred to as MS2 or MSMS) has to be performed.
Basically, first intact peptides are scanned (precursor scan), which are
then dissociated (fragmented) and analysed again (product ion scan).
The product ions can be dissociated further and analysed again, to ob-
tain an even finer resolution of the amino acid sequence (MS3, or more
generally MSn). In general experiments, MS2 and MS3 are the most
common.
Tandem mass spectrometry is performed in two ways: tandem-in-
space or tandem-in-time. Tandem-in-time mass spectrometry performs
the discrete steps (ion selection, activation, and product ion analysis)
in the same mass analyser, sequentially in time, while with tandem-
in-space mass spectrometry each level of mass spectrometry is per-
formed in separate mass analysers. Tandem-in-space mass spectrometry
is done, for example, in triple-quadrupoles, which have three quadru-
poles: the first and third act as mass analysers, while the middle quad-
rupole (or hexa-/octopole) acts as a collision cell. The collision cell is
filled with a noble (inert) gas. As the molecules move through the colli-
sion cell, they collide with the gas and break into smaller pieces. This is
called collision induced dissociation (CID). Every next level would re-
quire another collision cell and mass analyser, so this is really only feas-
ible up to MS3. Higher-order tandem MS is also possible by exchanging
the last quadrupole with a linear ion trap, combining tandem-in-space
(for MS2) with tandem-in-time (for MS3) mass spectrometry. Similarly,
the Orbitrap does not have the option to perform tandem MS by it-
self, but needs a dedicated ion trap for ion isolation and dissociation,
prior to analysis of fragments in the Orbitrap. To achieve better frag-
mentation, the molecules can be (further) dissociated in the C-trap, or













































Figure 2.3: Fragment ion definition for the fragments observed in tandem
mass spectrometry.
the C-trap to be transferred into the Orbitrap. This is called higher-
energy C-trap dissociation, or, as the dissociation generally happens
outside the C-trap, higher-energy collisional dissociation (HCD).
Usually the aim is to break each peptide once, leading to peptides
with the original N-terminus and peptides with the C-terminus, but no
peptides with neither or both. Breaks between two amino acids in the
peptide sequence can occur in three places: at the C-terminal side of
the α-carbon of the ‘left-hand’ amino acid, at the N-terminal side of
the α-carbon of the ‘right-hand’ amino acid, or at the bond between
the two amino acids. The resulting peptide fragments are named, for
ease of reference, according to the break point from N- to C-terminus:
a, b, and c ions for the fragment ions containing the N-terminus, and
x, y, and z ions for those containing the C-terminus. Additionally, they
are numbered according to the number of amino acid side chains they
contain (Figure 2.3).
Fragment spectra only show intensity vs m/z , thus for proper iden-
tification of fragment ions, the charge state needs to be taken into
account. Furthermore, the same fragments can be present in the spec-
trum with different charge states, adding additional complexity to the
fragment spectra. To make interpretation simpler, charge deconvolu-
tion, using the isotopic distribution, is applied to spectra with multiply
charged fragments, calculating the singly charged m/z for multiply
charged fragments. This is mainly a challenge for ionisation with ESI,
which generally leads to multiply charged ions, while MALDI mainly
generates singly charged ions.
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2.1.8 Mass spectrum files
In the process of peptide analysis and fragmentation, packets of ionised
molecules are sent into the detector one by one, recording the m/z and
the intensity of the signal at each m/z , resulting in a raw mass spectrum
for each of these packets. The number of mass spectra from the analysis
of a single sample easily runs in the thousands, leading to data in the
order of several GB for a single sample.
A mass spectrum is usually displayed as a diagram with m/z on
the horizontal axis and the intensities on the vertical axis. Due to the
nature of detectors and the reality in which the molecules exist, the
m/z is not measured with infinite precision. The peaks are thus not
straight lines, but rather stretch over a small m/z range, dependent
on the resolution of the instrument. With low-resolution instruments
from a couple of decades ago, nearby peaks regularly merged with each
other, making interpretation very difficult. For further processing of the
spectra it is necessary to summarise the small m/z ranges into peaks
at a single m/z , generating a peak list (Eidhammer et al., 2013).
The generation of this peak list from the raw mass spectra is not
trivial: even when there are no molecules in the detector, the detector
still ‘detects’ a certain amount of background noise. This baseline meas-
urement needs to be removed from all intensities, but is not the same
across the whole experiment. Furthermore, summarising the intensities
of a peak across a m/z range into a single intensity can be done in sev-
eral ways (Eidhammer et al., 2013). The simplest way is to just pick the
intensity at the apex of the curve. Alternatively, a model can be used
to approximate the curve, e.g. by fitting a quadratic curve through the
apex and two points on either side of the apex, or by fitting a Gaussian
(or Laurentian) curve through the apex. From these estimated curves
the area under the curve is calculated to be the intensity of the meas-
urement.
2.2 Interpreting mass spectra
After obtaining the peak lists, peptides have to be identified and quanti-
fied. Peptide identification is done on the basis of the fragment spectra,
while the quantification is usually based on the data in MS1 spectra. An
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important exception is experiments with isobaric labels, which also per-
form quantification on the fragment spectra. When the peptides have
been identified, they have to be mapped to the proteins they came
from, referred to as the protein inference problem, and subsequently
protein abundances have to be calculated. The protein identifications
and abundances then form the basis for further statistical analysis.
2.2.1 Peptide identification
The generated peak list is used to identify the peptide(s) present in the
mass spectrum. This can be done by comparing the spectra to fragment
spectra in a pre-generated database, to a spectral library, or by de novo
sequencing. To make a database with theoretical fragment spectra, pro-
tein sequences are downloaded (e.g. from UniProt (The UniProt Con-
sortium, 2019) or RefSeq (O’Leary et al., 2016)) and from these protein
sequences a decoy database is generated. The usual strategies to gen-
erate the decoy proteins are to either reverse the protein sequences, or
to generate random protein sequences (Edwards, 2017; Elias and Gygi,
2007; Moosa et al., 2020). The protein sequences are then digested in
silico (algorithmically, on the computer) with the same rules as the en-
zyme used in the experiment. As in the sample processing, the enzyme
will usually miss some cleavage sites and the in silico digestion is thus
performed allowing for a small number of missed cleavages. The result-
ing peptides are then fragmented, leading to a series of expected peak
positions on the scale of m/z . These peak positions can then be com-
pared to the peaks found in the experimental spectra, and scores for the
compatibility can be computed to estimate the level of certainty con-
cerning matching theoretical peptides. By using both a relevant protein
database and a decoy database it is possible to estimate probabilities
of chance matches (Edwards, 2017).
Especially for complex organisms, and including multiple PTMs, the
database can become extremely large. In addition, the height of the
fragment peaks is often not taken into account, while it does contain
valuable information (Silva et al., 2019). An alternative for theoretical
fragment library search is to create a spectral library from experimental
fragment spectra. First, a number of runs is done, identifying peptides
in the spectra as before. The identified experimental spectra then form
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the spectral library against which the fragment spectra from subsequent
runs are compared. This vastly reduces the size of the database to com-
pare against, as only peptides (with PTMs) that have been identified
before are included in the spectral library. Additionally, peak heights
can be used for more accurate scoring of the spectrum comparisons
(Craig et al., 2005; Shiferaw et al., 2020). Finally, a recent approach is
to generate a spectral library from a sequence database using instru-
ment specific peptide detectability predictions (Yang et al., 2020).
When mapping against a protein database, one is only able to identify
peptides that can come from proteins in that database. For well annot-
ated species this can be the main driver for peptide identification, but
for species lacking annotation many peptides are likely to be missed
or identified incorrectly. To identify peptides from fragment spectra
without an annotated database, one can perform de novo sequencing.
This is done by inferring the amino acid sequence by looking at the dis-
tance between different peaks. Depending on the dissociation strategies
some fragment ion pairs are more likely than others (Gross, 2017). Ad-
ditional evidence that a peak in the spectrum comes from a fragment
ion (instead of e.g. background noise) presents itself when peaks for
the other fragmentation points are present. By mapping the distance
between two neighbouring ion peaks of the same series, e.g. two y-ions,
to amino acid masses, one can infer which amino acid is present at a
particular point in the sequence (Figure 2.3). Repeating this process for
all peaks can in many cases lead to identification of most amino acids
in the peptide, and their sequence, for high-quality fragment spectra,
as in Figure 2.4. De novo sequencing can also be performed in addition
to spectrum matching, to attempt to identify unidentified experimental
spectra. The generated peptide sequence(s) can additionally be com-
pared to the database.
Both for spectrum matching and de novo sequencing the incorpora-
tion of possible PTMs can dramatically increase the search space (Ver-
heggen et al., 2016). Fixed modifications, i.e. modifications that are
assumed to affect all relevant amino acids, simply replace those amino
acids with their modified counterpart when building the database. A
standard fixed modification for mass spectrometry analyses is carbam-
idomethylation of cysteine. When generating the peptide database the
cysteine residues are all replaced by their modified counterparts, leaving
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Figure 2.4: Simulated fragment spectrum with de novo annotation for the
peptide ESRPACASR. Fragments are singly charged, peak heights are predicted
from the singly charged peptide with MS2PIP (Gabriels et al., 2019). Blue: b-
ions, red: y-ions. Distances between peaks correspond to the annotated amino
acid residue masses.
the database the same size. Variable modifications, on the other hand,
are modifications that might or might not be present on the amino acid
residues, e.g. oxidation of methionine and phosphorylations. These are
usually of much lower abundance, and for each of the relevant residues
it would have to be checked whether the modified or unmodified residue
fits, thus dramatically increasing the size of the database and the search
space for de novo sequencing.
2.2.2 From peptide to protein abundance
With peptides identified, the next steps are to infer the proteins from
the peptides, and, subsequently or simultaneously, calculate protein
abundances. Unfortunately, neither step is trivial, and many approaches
are available.
Protein inference To determine which protein a peptide came from,
the only information available is the amino acid sequences of the pep-
tide and the proteins. Unfortunately, there are many peptides that can
come from multiple proteins. This makes it difficult to determine which
proteins are present in the sample, based only on the identified pep-
tides. This challenge, mapping peptides to proteins, is called the protein
inference problem.
Given a set of identified peptides and a set of proteins from which
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Figure 2.5: Different scenarios for protein identification. Unique peptides are
blue (as in (a)), shared peptides red (as in (b)).
the peptides could have come from, there are six general ways peptides
can map to proteins. Nesvizhskii and Aebersold (2005) developed a
nomenclature to distinguish these scenarios, and named them distinct,
indistinguishable, shared peptides only, differentiable, subset, and sub-
sumable (Figure 2.5).
The simplest scenario is where the proteins have no shared peptides.
Each peptide belongs to only one protein, so it is clear that both pro-
teins occur in the sample and which peptide comes from which protein.
These proteins are called distinct proteins (Figure 2.5a). The opposite
2.2 Interpreting mass spectra 25
happens when all the peptides from two proteins are shared by those
two proteins (Figure 2.5b). None of the peptides is unique to one of
the proteins, so either one or both of the proteins is present in the
sample, but it is impossible to know which. When there are more than
two proteins this generalises to a group of proteins that is identified by
shared peptides only (Figure 2.5c). In this set there is no peptide that
is unique to one protein, though any pair of proteins might not share
all their proteins with each other.
If instead the proteins share some peptides, but both have at least one
unique peptide, the proteins are differentiable and both are present in
the sample (Figure 2.5d). This is in contrast to the situation in which
all peptides in the set belong to one protein, and a subset of these
peptides belongs to the other protein, but this second protein does
not have a unique protein. This second protein is then called a subset
protein (Figure 2.5e). A similar scenario is the one with a subsumable
protein (Figure 2.5f). This occurs when a protein shares peptides with
two other proteins, which both have at least one unique peptide and
only share peptides with the first protein, but not with each other.
While the last two proteins are definitely present in the sample, it is
unclear whether the subsumable protein is.
The reasons why non-unique peptides occur are numerous. For ex-
ample, as a gene can produce many different protein isoforms, these are
likely to share peptides. Proteins that originate from alternative splice
forms would only have distinct peptides for those peptides that contain
a splice site. Furthermore, proteins with (different) PTMs are indis-
tinguishable apart from the peptides where the modification(s) exist.
Similarly, cleavage of a signal or transit peptide might not be observ-
able unless the cleaved peptide is observed. Ideally, proteins that are
indistinguishable should be presented as protein groups, although that
might be challenging for subset and subsumable proteins.
Protein quantification Given the different ways the peptides belong-
ing to a protein can be shared with other proteins, there are many
ways peptide abundances can be summarised into protein abundances.
Limiting the abundance calculation to unique peptides, might ignore
most of the peptides that could belong to a protein. In this simple case,
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where all peptides are certain to come from the same protein, the mean
or median of the peptide abundances can be used as a protein abund-
ance. Exclusively using this strategy for all proteins will exclude many
peptides and potential proteins.
The challenge becomes more complex for sets of proteins that are
identified by shared peptides only. Taking the example in Figure 2.5c,
the relative abundances of the three proteins could be approached as
a constraint satisfaction problem. However, the peptide abundances
are not perfect, and the number of proteins with shared peptides is
usually much larger than what is depicted in the examples. Especially
taking into account different proteoforms, the summarising of the pep-
tide abundances into one protein abundance is an incredible challenge
(Plubell et al., 2021).
As there are many different ways to decide which proteins are (not)
present in the sample in the above situations, different algorithms can
give different sets of identified proteins and different protein abund-
ances. Typically, protein inference and quantification is done in an
integrated software pipeline, collecting tools for each step in one in-
terface. Even so, oftentimes the different steps in the protein inference
and quantification process are treated as distinct, and only point es-
timates for quantifications are given which hides variability in peptide
abundances and subsequent uncertainty of the protein quantifications.
Triqler/Quandenser (The and Käll, 2019, 2020) recently proposed an
alternative, taking uncertainty of all previous stages into account when
estimating protein abundances and outputting posterior distributions
rather than point estimates.
2.3 Analytical approaches
Depending on the goals of the experiment, different types of analyses
might be appropriate. Here the focus is on quantitative proteomics us-
ing mass spectrometry. Other types of analysis, such as which proteins
interact with each other or what the three-dimensional structure of a
protein is, are performed with different experimental set-ups and in-
struments and will not be discussed here. The most common goals of
quantitative proteomics studies are to find the effect of an interven-
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tion, or differences between populations. Another general distinction is
between targeted or discovery experiments. Furthermore, within discov-
ery experiments the main distinction is between data-dependent aquis-
isiton (DDA) and data-independent aquisition (DIA). Additionally, all
these experiments can be performed with various different labels or as
label-free (Eidhammer et al., 2013).
2.3.1 Targeted vs discovery
A usual sequence of proteomics experiments starts with a discovery
study, to get a rough idea of the proteins present in the samples and to
generate a preliminary list of proteins that might be interesting to study
in the given situation. This is then followed by a targeted experiment
where the focus is specifically on the peptides or proteins in that list.
By only targeting a relatively small number of proteins/peptides, more
accurate and stable results can be achieved at the cost of vastly reduced
coverage.
In discovery studies, the goal is to screen for differences between two
(or more) populations. These can be subjects which have e.g. received
a certain drug or have a certain disease. The first questions are which
proteins can be found, and which are differentially expressed between
the populations. As these are screening experiments, the protein abund-
ances found in these experiments are not as accurate as one would like
for definitive answers. Rather, the goal is to select a small subset of
the proteins, e.g. the top differentially abundant proteins, for further
study. This selection is then augmented by other proteins that are in-
teresting, e.g. because of previous research or because they have roles
in the same, potentially relevant, pathways.
In targeted experiments only a small number of proteins/peptides
are quantified, e.g. the resulting list of proteins from the discovery ex-
periment. If the proteins have unique peptides (or peptide fragments)
after digestion, these can be selected and isolated by the mass ana-
lyser. As only a relatively small number of peptides are targeted, this
gives the opportunity to perform absolute quantification using syn-
thetic peptides. These peptides are assembled with a specific mass dif-
ference, which is achieved by synthetically generating the peptide with
one amino acid replaced by a heavy version containing stable (heavy)
28 Mass spectrometry-based proteomics
isotopes of carbon, nitrogen, and hydrogen (i.e. 13C instead of 12C, 15N
instead of 14N, and 2H (deuterium) instead of 1H elements). As the
amount of the synthetic (heavy) peptide(s) in the sample is known,
and the same across samples, this can be used as a reference to cal-
culate the actual amount of the peptide observed, even when there
are small differences in the acquisition performance between samples
(Kirkpatrick et al., 2005).
2.3.2 Labelled vs label-free
For discovery experiments there is a choice between labelled or label-
free analysis. In label-free analysis, the peptides/proteins are loaded
onto the mass spectrometer one sample at a time without any labels
added to the peptides/proteins in the sample (Figure 2.6a). Comparing
proteins and peptides between samples thus has added variance due
to differences in sample acquisition. By using labels, one can directly
compare peptide abundances between samples avoiding the variability
between different runs. Different labels have different properties and
use-cases, but the main idea is the same. The labels are added to the
different samples (e.g. iTRAQ, TMT), cell cultures (e.g. SILAC), or
are fed to animals in the form of special food. The labelled samples are
then combined into a single pooled sample, with the number of samples
that can be differentiated depending on the number of distinct labels.
Isotopic labelling is performed by using specific food, in the case of
animals, or growth medium, in the case of cell lines. For clarity, the
examples here concern only animals and food, though the same con-
cepts apply to cell lines and growth medium. The isotopic labelling
is done by using food with monoisotopic amino acids for one animal,
and food with stable heavy isotopes of one of the amino acids for the
other animal (Figure 2.6b). For example, when the food contains ar-
ginine with 13C, the mass difference between heavy and light peptides
is calculated as the number of carbon atoms in arginine residue (see
Table 1.1), times the number of arginines in the peptide, times the mass
difference between 13C and 12C (see Table 2.1). A peptide containing
one arginine would thus present a mass difference of just over 6 Da.
The mass difference between the heavy and light peptides depends on
the number of modified amino acids in the peptide, and peptides not









Figure 2.6: Different types of labelling in proteomics experiments. See main
text for details.
containing any modified amino acid are indistinguishable between the
two samples.
Isobaric labels are instead attached to each of the peptides in the
sample after digestion (Figure 2.6c). Sample preparation is mostly as
in label-free studies, except that near the end of sample preparation a
sample-specific label is added to each sample, after which the samples
are combined into one pooled sample. The labels are designed with
three distinct parts: (i) one chemical group that can bind to a part of
the peptides, e.g. an amine specific group that attaches to the peptide
N-terminus, (ii) a reporter ion, defined by its specific mass to differenti-
ate it from the other labels in the same set, which can attract a charge
and is preferentially dissociated at a specific chemical bond so it can be
observed in fragment spectra, (iii) and a balancer group which makes
sure the masses of all the different labels are the same. This way the
relative abundances of the peptide in the different samples are visible
in the fragment mass spectra.
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Thus, isotopic labels allow to avoid the variance between samples
introduced during the experiment, while isobaric labelling allows to
avoid adding variance after digestion. In label-free workflows, however,
the full experimental variance is added to the biological variance.
2.3.3 Tandem mass spectra acquisition
Ionised molecules are processed in small groups, which are collected
during a short period of time. The m/z of the molecules in such a
group are analysed (the precursor scan), and subsequently a decision
is made which molecules (which m/z ranges) are fragmented for MS2.
In the most common acquisition strategy, data dependent acquisition
(DDA), the m/z ranges corresponding to the highest MS1 intensities
are selected to be analysed further with MS2. For each of these m/z
ranges, the peptides are directed into the collision chamber, such that
each fragment spectrum is likely to contain the fragments of a single
precursor ion. To prevent the repeated selection of very high abundant
peptides dynamic exclusion of m/z ranges can be used.
The selection of a m/z range corresponding to peaks in the MS1
spectrum ideally leads to the selection of a single peptide species. In
that case the MS2 fragment spectra contain fragment peaks originat-
ing from a single peptide. However, often a peak can consist of two
or more coeluting peptides of the same m/z , leading to MS2 fragment
spectra contain peaks originating from a multiple peptides. These chi-
meric spectra have to be deconvoluted in order to identify all present
peptides (Dorfer et al., 2018).
As only the most intense precursor ions are selected for MS2, many
of the low abundant peptides will not be fragmented, and subsequently
not identified as identification is done based on the fragment spectra.
In different samples the top most abundant peptides in each precursor
scan might also be slightly different, leading to some peptides getting
selected in one sample, but not in another. Longer elution gradients
spread the molecules more and can alleviate this problem to a certain
extent, at the cost of longer run-times per sample.
An alternative is instead to fragment all the molecules in the pre-
cursor scan, termed data independent acquisition (DIA). The selection
window for which molecules to fragment in each round is much wider
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than in DDA, leading to fragment spectra containing fragments from
multiple, potentially many, precursor ions. Interpretation of the spectra
is therefore much more challenging than in DDA (Yang et al., 2020).
An additional advantage is that the sample volume needed for DIA is
less and the throughput is higher. Both DDA and DIA are used for
label-free analyses, however, as in DIA multiple precursor ions can be
fragmented together, this method is not suitable for labelled experi-
ments, e.g. the intensities of isobaric tags would be a combination of
the intensities of all selected precursors.
For targeted analysis the main approaches are selected reaction mon-
itoring (SRM) and parallel reaction monitoring (PRM). In both SRM
and PRM, first a peptide precursor is selected in MS1, subsequently
a complete fragment scan is performed in PRM, while in SRM only a
select number of fragments is selected (Ankney et al., 2018). This addi-
tionally allows the use of synthetic peptides for absolute quantification.
2.4 Analysis of intact and digested proteins
A major distinction in proteomics approaches is the difference between
top-down and bottom-up proteomics. In addition, peptidomics shares
some aspects of both proteomics techniques, and presents its own chal-
lenges and opportunities.
2.4.1 Top-down proteomics
When intact proteins are loaded onto the mass spectrometer, this is
called top-down proteomics. By analysing and fragmenting the intact
proteins, the protein inference problem is avoided, additionally making
it possible to identify different proteoforms created by e.g. PTMs and
endogenous proteolysis. In case the proteins are not denatured, even
protein aspects such as folding and complexes can be analysed (Brown
et al., 2020). Fractionation and fragmentation of large molecules is more
challenging than for smaller peptides, and reduces the sensitivity of the
measurements. With standard LC-MS only around 100 proteoforms can
be identified, with limited coverage above 30 kDa (Brown et al., 2020).
Longer columns or different fractionation strategies are needed to lower
the sample complexity and increase the sensitivity. The mass spectra of
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fragmented intact proteins contain many different product ions, which
leads to a low signal to noise ratio, making interpretation of the spectra
challenging. Low abundant proteins and proteoforms are thus hard to
find in top-down proteomics (Brown et al., 2020; Cupp-Sutton and Wu,
2020; Schaffer et al., 2019).
2.4.2 Bottom-up proteomics
In bottom-up proteomics one starts by denaturing the proteins, break-
ing the noncovalent bonds and converting them into their primary
structure, a flexible polypeptide chain, which is then digested into smal-
ler peptides by a protease. The most common protease is trypsin, which
cuts only after (at the C-terminal side of) arginine and lysine, unless
followed by a proline, leading to peptides usually consisting of less than
25 residues (Eidhammer et al., 2013; Twyman, 2014). These peptides
can attract a limited number of charges, and can produce fewer differ-
ent fragment ions, leading to easier to interpret fragment spectra with
higher signal to noise ratios. Mapping the peptides to proteins (the pro-
tein inference problem), and recombining the peptide intensities into
protein intensities present significant challenges. Additionally, a pro-
teoform with modifications on multiple peptides is impossible to distin-
guish from individual proteoforms with a single modification (Schaffer
et al., 2019).
2.4.3 Peptidomics
Peptidomics has aspects of both bottom-up and top-down proteomics,
as intact endogenous peptides are loaded onto the mass spectrometer.
Interest is usually in peptides of less than 15 kDa, including disease-
specific small protein fragments and signalling molecules. The identi-
fication of the peptide necessarily has to rely on fragment spectra, as
amino acid sequences of unknown peptides are not known. The identi-
fication therefore combines database searching and de novo sequencing.
PTMs influence the biological function of peptides, and thus also need
to be taken into account. Furthermore, the terminals are not (neces-
sarily) cleaving sites for a known enzyme, dramatically increasing the
search space (Schrader, 2018).
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2.5 Small peptides and single amino acids
In general proteomics and peptidomics experiments, peptides with only
a single charge are ignored as these are likely to be contaminants. How-
ever, this workflow ignores small peptides that attract at most one
charge, possibly discarding valuable information. Recently these very
small molecules have become a focus of research for different diseases
and bodily fluids (Fonteh et al., 2007; Martelli et al., 2014).
While there exist several kits that allow the specific targeting of single
amino acids and some small peptides (e.g. EZ:FAAST (Badawy et al.,
2008) and aTRAQ (Held et al., 2011)), these require special sample
handling and are thus not easily combined with standard proteomics
workflows. Metabolomics approaches such as calculating the fragment-
ation tree of the molecules are resource intensive and can be overkill for
the analysis of a set of compounds with known structures (Böcker and
Rasche, 2008). The number of charges a peptide can attract depends on
the pH and the constituent amino acids. As isobaric labels need to be
able to attract a charge, all labelled peptides (including labelled single
amino acids) can attract at least one charge. When these singly charged
peptides are fragmented in MS2 they can potentially be separated from
contaminants due to the isobaric tags. For small enough peptides and
a limited number of PTMs, the possible fragments ion masses can be
calculated, and mapped to the fragment spectra. Thus, even very small
peptides that would normally not be able to attract a charge become
available for analysis by using isobaric labels and also fragmenting the
singly charged peptides.
This novel approach is further explored in Paper II .

3 Statistical analysis of proteomics
data
When protein abundances have been quantified, the next step is usually
to look for differences between the populations of interest. Proteomics
studies are often split into two parts: first a discovery experiment, in
which as many proteins as possible are identified and quantified, which
serves to find a set of ‘interesting’ proteins that will be studied more
closely in a second experiment, often called a verification or validation
experiment. This second experiment should be performed with new
samples, and focuses on only a relatively small set of proteins, usually
employing a targeted method and absolute quantification. Finally, the
results of the statistical analysis have to be put in a biological context,
which is often done with pathway analysis.
3.1 Comparison of protein abundances
In complex samples, the protein abundances are usually assumed log-
normally distributed, which practically means that the errors are as-
sumed to arise from a multiplicative process. By applying a log-trans-
formation, the relationship between the variances becomes additive,
making standard least squares approaches to estimation applicable. The
choice of base for the logarithm is usually chosen pragmatically to aid
interpretation. As differences in protein abundances between groups are
usually given in fold changes, the most commonly used base is two.
3.1.1 Differences between two groups
With quantified protein abundances, a natural first step is to perform
a per protein analysis to look at differences between the populations
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for each protein separately. The simplest way to compare normally dis-
tributed continuous values, such as protein abundances, between two
populations (or treatment groups) is with a two-sample t-test. As the
protein abundances (for a single protein) are not the same for each sub-
ject in each of the two treatment groups, the variability of the meas-
urements within each treatment group should be taken into account.
Thus, the test statistic is defined as the difference between the group
means divided by the weighted average of the sample standard devi-
ations. When the variation within each group can be assumed to be
(roughly) equal, the standard deviations can be pooled, and the test
statistic is defined as (Kutner et al., 2005)
t =





with x̄1 and x̄2 the observed sample means, d0 the mean difference
under the null hypothesis, and sp the pooled sample standard deviation
s2p =
s21(n1 − 1) + s22(n2 − 1)
n1 + n2 − 2
(3.2)
The null and alternative hypotheses associated with the test statistic
are
H0 : µ1 − µ2 = d0 (3.3)
H1 : µ1 − µ2 6= d0 (3.4)
Usually d0 is set to 0 to test whether there is ‘no difference’ between
the two means. To test the null hypothesis the observed t is compared
to the appropriate cumulative density from the t-distribution with the
appropriate degrees of freedom. Degrees of freedom indicate the number
of values that are free to vary with the given test statistic. Here the
comparison is between two means, each of which ‘costs’ one degree
of freedom, the null distribution thus being tn1+n2−2. The cumulative
density for a two-sided test (as shown above) is taken at α/2, where
the usual cut-off for α is 0.05.
When one of the treatment groups is likely to be more variable than
the other it is not appropriate to pool the standard deviations. This
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can happen, for example when a healthy population is compared to a
population containing subjects with diverse disease progression states.






















Large differences between the two test statistics only occur when there
are substantial differences in sample sizes and/or standard deviations
(Boneau, 1960; Lumley et al., 2002; Moser and Stevens, 1992).
In case of severe departures from normality it is more appropriate
to use a rank-based test, such as the Wilcoxon rank-sum test, also
known as the Mann-Whitney U test. With this test the ranks of the
abundances of each group are summed and used as test-statistic, and
the null distribution is generated by enumerating all possible rank sums,
given the sample sizes. The choice of test should ideally be made as part
of the design of the experiment.
To test for normality when the data has been collected presents sev-
eral problems. Firstly, a test of normality, such as the Shapiro-Wilk
test, has very low power with small sample sizes. With large sample
sizes, approximate normality is achieved due to the central limit the-
orem, which ensures that the t-test is appropriate. However, with large
sample sizes small departures from normality can be identified, reject-
ing normality at a level where the t-test is still appropriate. Secondly,
departures from normality can present as skewness (one tail longer than
the other) and/or as kurtosis (longer or shorter tails). Of these, only
skewness has a detrimental effect on the t-statistic when the skew is in
opposite directions in the two groups (Boneau, 1960; Box, 1953; Lumley
et al., 2002).
3.1.2 Multiple testing correction
With per-protein analyses, p-values for the individual proteins should
not be viewed in isolation of each other. The two common ways of
correcting for multiple testing are by limiting the family-wise error
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rate (FWER), or by limiting the false discovery rate (FDR). FWER
limits the probability of one falsely rejected hypothesis (i.e. the chance
of one false positive) to a specific level, while FDR limits the fraction of
the expected number of falsely rejected hypotheses amongst all rejected
hypotheses.
In discovery studies the interest is in finding a limited set of proteins
for further study, as false discoveries can be filtered out again later, as
long as there are not too many of them. It is more important not to
have many false negatives, proteins that are important for the difference
between the treatment groups but are discarded for further analysis.
FWER would thus be too strict for this setting, and FDR the better
choice (Hastie et al., 2009).
The FDR estimation procedure that is most used in proteomics is the
Benjamini-Hochberg method (Benjamini and Hochberg, 1995) which
starts from an ordered list of the m p-values (ascending) and rejects
all hypotheses i : pi <
i
mq, with m the total number of hypotheses
(proteins) and q the required FDR level. Instead of calculating cut-off





i . Hypotheses where p
∗
i < q are then rejected.
One of the assumptions underlying most FDR estimation procedures
is that the p-values of all the hypotheses follow a mixed distribution,
with the p-values of the non-differentially abundant proteins following
a uniform distribution between 0 and 1, and the p-values of the other
proteins concentrated near 0. This assumption can be tested by e.g.
generating a histogram from the p-values or using calibration plots as
described in Gianetto et al. (2016).
As the FDR is a step-wise procedure, selecting proteins from the list
of rejected hypotheses invalidates the FDR, i.e. the fraction of false
positives can be higher or lower than the chosen level. This is, however,
common practice in proteomics discovery studies (Schwämmle et al.,
2020). In Goeman and Solari (2011), a different approach is taken,
which is especially relevant for these settings. Here, a closed testing
procedure is used to calculate the expected number of false discoveries
for every subset of hypotheses simultaneously. Thus, when a researcher
has performed the per-protein analysis, selects some proteins based on
FDR and some proteins based on their expert knowledge, the expected
number of false discoveries can be found by applying this procedure.
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3.1.3 Testing multiple variables
If there are additional variables that have to be taken into account, such
as batch- or sex-effects, the preceding tests are not appropriate. Ignor-
ing batch-effects, or other variables that can influence the difference
between the treatment groups, can lead to incorrect inferences (Box
et al., 2005). Instead a (linear) model should be employed to estim-
ate the effect of all variables under consideration. For example, when
there is a binary treatment variable (e.g. Placebo vs Treatment) and
two batches, a model can be defined as
Yi = β0 + β1Ti + β2Bi + εi (3.6)
with Yi the protein abundance of protein i, Ti and Bi indicator variables
for the treatment and batch respectively, β0 the intercept, β1 and β2
the estimated effect of the treatment and the batch respectively, and εi
the deviation of subject i from their expected value given the model.
εi is thus a random error with mean 0 and variance σ
2 (Kutner et al.,
2005).
When the interaction between the treatment variable and another
variable is also of interest, interpretation of the results becomes more
involved. Say there is a binary treatment variable (e.g. Placebo vs Treat-
ment) and two sexes (Female and Male), and the interaction between
the treatment and sex is expected to be of interest. A model can then
be defined, similarly as above, as
Yi = β0 + β1Ti + β2Si + β3TiSi + εi (3.7)
The effect of the treatment is now partly the marginal treatment effect
β1 and partly the interaction effect β3. This makes (semi-)automated
selection of ‘interesting’ proteins for the discovery experiments difficult,
but could aid with interpretation of validation experiments.
As the test statistic is defined by the difference between the groups
divided by the spread of the data, proteins with small fold change and
small variance can appear highly significant. To stabilise the variance,
pooling variances from all proteins and pulling the variances of the
individual proteins towards this pooled variance, an empirical Bayes
approach such as LIMMA can be used (Smyth, 2004).
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3.1.4 Missing values
Often many of the quantified proteins contain missing values for some
of the subjects. There are generally two ways missing values can be
handled in a statistical analysis: either variables or subjects with miss-
ing values are removed from the analysis, or the missing values are
imputed. Removing variables or subjects can lead to biased inferences,
and should not be done without thorough justification. Imputation has
to be based on the type of missingness and allow for a quantification
of the uncertainty of the imputations (Molenberghs et al., 2015; van
Buuren, 2018).
One of the simplest imputation methods is to replace the missing
values by the median of the observed values, or half of the lowest ob-
served value. By imputing a single value, the assumption is made that
the imputed value is the only possible true value, reducing the overall
variance in the data. Moreover, as usually none of the protein abund-
ances are exactly alike, it would actually be highly unlikely that all
missing values are exactly the same.
One way of taking the likely location and variability of the data into
account is to sample imputed values from a normal distribution based
on the mean and variance of the observed protein abundances. The
Perseus software takes this approach, assuming values to be missing
due to low abundance (Tyanova et al., 2016). This requires a strong
assumption on the expected location and variability of the missing val-
ues. In addition, as each missing value is imputed by a single imputed
value, the uncertainty of each imputation is not carried forward into
downstream analysis.
Instead, the analysis of missing values should be either part of the
downstream data analysis (i.e. joint modelling), or each missing value
should be imputed multiple times, such that the uncertainty of the
imputation can be taken into account (Molenberghs et al., 2015; van
Buuren, 2018).
The mechanism by which values go missing can be categorised into
three main categories: missing completely at random, missing at ran-
dom, and missing not at random (Table 3.1). Censored variables are
included in the missing not at random category, but are interesting
in and of themselves. Thorough treatment of the handling of miss-
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Table 3.1: Mechanisms for missing values. MCAR: Missing com-
pletely at random. MAR: Missing at random. MNAR: Missing not
at random. Censored values are also MNAR.
Mechanism Missingness dependency
MCAR Independent of both observed and unobserved
variables
MAR Dependent only on fully observed variables
MNAR Dependent on unobserved variables
Censored Dependent on missing values themselves
ing values in different fields and manners can be found in handbooks
on missing values such as Molenberghs et al. (2015) and van Buuren
(2018), which provided the basis for the following descriptions.
When values are missing completely at random (MCAR), the miss-
ingness (whether an observation is observed or not) is independent of
both observed and unobserved variables. Thus the missing values can
be ignored (i.e. the subjects can be left out of the analysis) without
biasing the analysis. Unfortunately, this hardly ever happens.
When values are missing at random (MAR), the missingness is de-
pendent only on fully observed variables. Only when all the variables
that influence the missingness are included in the analytical model can
the missingness be ignored. The assumption that the missingness de-
pends only on some fully observed variables is impossible to verify,
thus in specific cases it will need to be substantiated with convincing
arguments about the nature of the data.
When the missingness depends on unobserved variables, the data is
not anymore ‘at random’. A special case of this presents itself when the
missingness depends on the missing values themselves. In a proteomics
context this could, for example, be peptides in data-dependent acquis-
ition that for some samples have too low abundance to be selected for
fragmentation. When this happens for all peptides of a protein, the pro-
tein in question can be missing for the subject. For these last two cases,
the data are missing not at random (MNAR), and the missingness will
either have to be modelled explicitly, or some bias in the inference will
have to be accepted.
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The missingness mechanism should be leading for the imputation
method used. For MCAR and MAR the imputation strategies can
be more or less general, depending only on the observed values and
(context-specific) dependencies between the variables. Contrariwise,
the imputation strategies have to be context-specific for MNAR, de-
pending on the reason why the values go missing. In a recent review
on imputation strategies for label-free proteomics experiments (Lazar
et al., 2016), it is concluded that: (i) both MCAR and MNAR val-
ues occur in proteomics data, in varying proportions; (ii) in absence of
knowledge about the nature of the missing values they show it is most
appropriate to consider them as MCAR/MAR; and (iii) when the miss-
ingness mechanism is known, on the other hand, it is better to use a
strategy dedicated to the type of missingness in the data.
As the data from the mass spectrometer is in the form of peptide
abundances, if no imputation is done at the peptide level, there is an
implicit assumption about the nature of the missingness mechanism
when deriving the protein abundance from (partially missing) peptide
abundances. Therefore, the imputation should ideally be performed at
the peptide level. It is also important to note that most current soft-
ware for imputation presents an imputed dataset without propagating
the uncertainty around the imputed values. Imputed values are thus
presented at the same level of certainty as observed values, which can
be potentially misleading. Instead, with multiple imputation or joint
modelling of the missing values and protein quantities/group differ-
ences the uncertainty about the missing values can be propagated to
protein quantifications and/or test statistics for differential abundances
(Goeminne et al., 2020; Lazar et al., 2016; Schwämmle et al., 2020; The
and Käll, 2019).
3.1.5 Handling outliers
Observed values that fall far outside the range of the other observed
values are called outliers. These form a challenge similar to that of miss-
ing values, as they can have biological reasons, in which case they are
valid values and care should be taken how to handle them, or technical
reasons, in which case they are invalid values that should be discarded.
Often it is not possible to find the reason why a value is an outlier. In
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Figure 3.1: The effect of an outlier on the mean and median of a sample. Blue
dots: main sample. Red dot: outlier. Solid blue line: mean excluding outlier.
Solid red line: mean including outlier. Dashed blue line: median excluding
outlier. Dashed red line: median including outlier.
information that is coded manually, coding errors can occur which are
easier to spot, e.g. a length in inches where there should be centimetres.
In computationally generated measurements as from a mass spectro-
meter, or in the quantification of proteins from their peptide values, it
is less obvious how to spot the nature of outliers.
A single outlier can greatly influence the mean of a set of values.
When comparisons between groups are based on the mean abundance
values, aberrant values can thus have a big influence on the results of
the analysis. To give an extreme example, when the observed values
are between 10 and 40, adding only a single outlier, say 100, the mean
already migrates outside the range of the original values (Figure 3.1,
solid lines). The median is the value that is both higher and lower
than 50% of the observed values. If instead of the mean, one would
perform inference based on the median, the influence of the outlying
value is much reduced (Figure 3.1, dashed lines). Thus, the median is
a measure of location that is robust against outliers. Similar statistics
exist for variance (e.g. median absolute deviation, interquartile range),
and for other statistics in general, e.g. rank-based statistics are robust
to outliers by design. The downside of robust statistics is that they and
their null-distributions are usually harder to compute.
3.1.6 Multivariate modelling and dimension reduction
When the number of subjects is smaller than the number of proteins,
the usual regression model with proteins as parameters is not identifi-
able. Thus, penalised regression or other methods should be employed
(Hastie et al., 2009). The two most common penalised regression meth-
ods are ridge regression and the least absolute shrinkage and selection
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operator (lasso), with elastic net being a combination of the two. These
methods impose a penalty on the size of the parameters, shrinking them
towards zero and towards each other. Where ridge regression shrinks
parameter values towards zero (but not at zero), the lasso does. Unfor-
tunately, the lasso has problems with highly correlated features, which
are common in proteomics data. By using elastic net, groups of correl-
ated features can be selected (or rejected) together. When the interest
is in specific, pre-defined groups of proteins (such as protein complexes
or pathways), a method such as (sparse) group lasso can be used.
Different machine learning techniques, such as e.g. random forests or
neural networks can also be used (see e.g. Hastie et al. (2009) for an
overview). These are, however, less easily interpretable as it is unclear
what the relation of the proteins are to each other and to the outcome of
the final decision rule. All the methods described in this section require
the optimisation of hyperparameters: extra variables that define, e.g.
the level of the penalty (for penalised regression), the depth and number
of trees (for random forests), or the depth of, and number of nodes in,
neural networks. To optimise these hyperparameters, models need to be
fitted multiple times with different values for the hyperparameters to
compare their performance. This can be done by splitting the data set
into a training-set and a test-set. For each value of the hyperparameters,
the model is fitted on the training-set, and the performance of the
model with the given hyperparameter values is subsequently tested on
the test-set, with the best performing hyperparameter values chosen for
the final model. The data set thus needs to be large enough that both
training- and test-set are of sufficient size to fit a decent model and to
give a meaningful performance evaluation, respectively. One thing to be
careful about is that the different treatment groups should be present in
sufficient quantities in both training- and test-set, and cross-validation
uses the data more efficiently (Hastie et al., 2009).
A different approach is orthogonal projections to latent structures
(OPLS) (Trygg and Wold, 2002). In this method, linear combinations
of all variables are generated that explain the maximum variance in the
protein abundance data in the direction of the variables of interest. Ad-
ditionally, variance orthogonal to (i.e. not correlated with) the variance
of interest is modelled, allowing for the analysis of both the differences
of interest and, separately, where additional noise in the data might
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come from. A natural comparison can be made with principal compon-
ent analysis (PCA), which generates linear combinations of variables
in the direction of the most variation in the data. This is however an
unsupervised method, in which an extra analysis is necessary to map
the principal components to either variables of interest or systematic
noise.
3.1.7 Peptide-centric and protein complex-based approaches
Several novel approaches apply a statistical model to peptide abund-
ances instead of the aggregated protein abundances. This both avoids
the loss of uncertainty of the protein abundance estimation, combining
abundance estimation and differential abundance testing. The approach
in Goeminne et al. (2016) is to fit a robust ridge regression on the pep-
tide abundances, while in The and Käll (2019) a Bayesian approach is
used.
A per-protein analysis assumes that the protein abundances are inde-
pendent of each other. Later in the analysis, when performing pathway
analysis, a major assumption is that proteins work together and the
abundance of proteins in active pathways should rather be correlated.
This can be seen clearly in enzyme inhibitors, which can inhibit the
production of some other enzyme. Similarly, proteins work together
with other proteins in protein complexes. When proteins are in the
same complex they could be assumed to have correlated abundances.
For example, several ways of performing statistical analysis on the pro-
tein complexes instead of the individual proteins are descibed in Goh
and Wong (2016a). This approach can find additional low-abundant
proteins that might be interesting for further analysis that would oth-
erwise be rejected.
3.2 Pathway analysis
It is common practice to first perform a per-protein analysis, followed
by a mapping of the selected proteins to pathways. This way the per-
protein analysis can hopefully be put into their biological context, and
additional potentially interesting proteins can be included in follow-up
analyses.
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As pathways are series of reactions, where the output of one reaction
is the input to the next reaction, they can be modelled as directed net-
works of reactions. Elements that are part of reactions can be proteins,
metabolites, RNA, and other molecules, from here on collectively re-
ferred to as molecules. The reactions can be seen as the edges between
molecules (e.g. KEGG (Kanehisa et al., 2016)), or as nodes with mo-
lecules connected to them (e.g. Reactome (Jassal et al., 2020)).
Looking at the complex nature of protein interactions and the path-
ways proteins are active in, a structural way of analysing the pathways
in which differentially abundant proteins participate can help with in-
terpreting the mapping of proteins to pathways. As proteins can par-
ticipate in multiple pathways, and pathways have different sizes (num-
bers of constituent proteins), the main idea is to calculate whether in
a pathway there are more proteins found differentially abundant than
expected by chance. What is expected by chance (and how to calculate
this) is mostly where the different pathway analysis methods differ.
In Khatri et al. (2012) three generations of pathway analysis meth-
ods are identified: over-representation analysis (ORA), functional class
scoring (FCS), and pathway topology (PT). ORA starts with a list of
differentially abundant proteins. Then, for each pathway, the number
of proteins in that list is compared to a background list of proteins,
e.g. all the identified proteins. A Fisher exact test (or similar) is then
used to test whether the proteins in the pathway are over-represented
in the input list of proteins. This only uses the number of differentially
abundant proteins, and thus ignores both the differential abundance
and the variability of the proteins in the list. Moreover, by only using a
subset of the identified proteins a (more or less arbitrary) cut-off has to
be made between proteins that are included and those that are deemed
irrelevant. The strict cut-off thus created can lead to a false dichotomy
between those proteins that are marginally included and those that are
marginally excluded. Finally, both the proteins and the pathways are
treated as independent from each other, which is paradoxical as pro-
teins in a pathway are unlikely to act independently from each other.
Similarly, pathways are connected to, and nested in, each other, and
are thus not independent of each other.
The main idea behind FCS is that both big changes in protein abund-
ance and many small changes within a pathway are important. Starting
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from the per-protein statistics of all identified proteins, these are then
transformed into a score for each pathway, which can depend on e.g. the
per-protein statistics, pathway-size, and correlations between different
protein abundances. Statistical significance can then be computed by
permuting class labels and comparing the proteins within each path-
way, or by permuting protein labels and comparing the proteins in the
pathway to proteins not in the pathway. With this approach arbitrary
thresholds are avoided, and the level of differential abundance is used
at least to some extent. However, the pathways are still considered as
independent from each other, just as with ORA.
PT methods follow the same steps as FCS, but make use of the
topology of the pathways when calculating the per-protein statistics.
The topology of a pathway is concerned with which proteins have roles
in the same reaction and what those respective roles are. If Protein A
is a catalyst of Reaction R, and Protein B is the output, the relation
between the two proteins would be different to when Protein A is an
inhibitor instead. Similarly, if Protein A and Protein B are in the same
reaction, their scores can be expected to correlate more than when they
are three reactions separated from each other. Elements like this can
potentially be used to compute more relevant scores for the pathways.
However, connections between pathways are still difficult to account for
with this approach.
3.3 Protein networks
3.3.1 Analysing network structure
Investigating the network structure of pathway databases can be done
at the level of the network or the level of the constituent proteins. At
the most general level, the network consists of a number of nodes (the
proteins) and edges between them (protein interactions). A group of
nodes which are connected to each other by edges is called a connec-
ted component (Harary, 1969). The nodes do not have to be directly
connected, i.e. if Node A is connected to Node B, and Node B is con-
nected to Node C, and there is no edge directly between Node A and
Node C, this is still one connected component. Additionally, the size of
the connected component can be defined by its diameter: between each
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pair of nodes in the connected component there is a shortest path, the
smallest number of edges connecting the two nodes. The longest of all
these shortest paths is the diameter of the connected component.
In a pathway network, the nodes are reactions with inputs and out-
put, and possibly catalysts and/or regulators, where the output of one
reaction can form the input to another reaction. This can also be seen as
a directed network, with edges going from input/catalyst/regulator to
output. The number of edges of a node is called the degree of the node,
with in-degree (the number of edges going to the node) and out-degree
(the number of edges exiting the node) defined for directed networks
(Harary, 1969). A straightforward way of looking at the importance of
a node is to look just at the degree of the node. However, this only gives
an indication of the immediate neighbourhood of the protein, which is a
rather limited perspective given the interdependent nature of the reac-
tions. Calculating the average number of steps in the network between
a protein and all other proteins in the network can act as a proxy of how
influential a protein could be across the network (Valente and Foreman,
1998).
Proteins often perform their functions together with other proteins in
protein complexes. All proteins in a complex have to be present for the
complex to be able to perform its function. The conceptual opposite is
proteins that are alternatives for each other in a reaction or a complex.
A set of such proteins can be annotated as an entity set. Then only
one of these has to be present for the reaction to be possible. This is
important for the pathway analysis, as finding multiple proteins in an
entity set might not be of as much interest as finding all proteins in a
complex, and makes the interpretation of the network more challenging.
The analysis of the structure of pathway databases is further explored
in Paper I .
3.3.2 Proteoform- vs gene-centric networks
Pathway databases are designed with specific goals and use-cases in
mind. For example, KEGG (Kanehisa et al., 2016) originated with a
focus on genes and metabolites, while Reactome (Jassal et al., 2020) is
centred around reactions involving metabolites and proteins. Aggreg-
ating the interactions of a protein into its parent gene combines the
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interactions of multiple proteins that originate from that gene, mak-
ing a protein-centric database necessarily more specific than a gene-
centric database. Similarly, proteoforms and PTMs are important for
specifying the function of a protein. These are increasingly commonly
identified in samples, but only to a lesser extent annotated in pathway
databases.
Where proteoform-level information is annotated in the pathway
database, it indicates minimal requirements on the status of a protein
to perform a reaction, e.g. phosphorylation at a given site. By creating
a proteoform-centric pathway network it becomes clear that the pro-
teoforms make the reactions more specific. Thus, analysing data at the
level of proteoforms leads to less irrelevant pathway hits. Additionally,
it shows that there are interactions between different proteoforms of
the same protein, which are lost at the protein (or gene) level.
Both these aspects can be illustrated with the interactions of annot-
ated proteoforms of the protein cellular tumor antigen p53 (P04637).
At the gene level, there are 220 interactions between the TP53 gene
and other genes (Figure 3.2a). Splitting the genes into their corres-
ponding proteoforms, the network expands to 23 annotated proteo-
forms originating from the TP53 gene, with 24 interactions between
two proteoforms originating from this gene, and 390 interactions with
227 proteoforms originating from other genes (Figure 3.2b).
While it is not always possible to identify the precise protein from a
gene, or proteoform of a protein, with the current methods, where these
can be identified they can possibly make the interpretation of the ex-
perimental results more specific. In Additional Paper I we developed a
tool to query the Reactome pathway database at different levels of spe-
cificity, allowing a more fine-grained interaction and pathway retrieval
depending on the level of the protein identifications in the experiment.
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(a) Gene-centric network (b) Proteoform-centric network
Figure 3.2: Proteoform-centric vs gene-centric network representation of the
protein cellular tumor antigen p53 (P04637). (a) Gene-centric network, with
other genes depicted as small blue nodes. (b) Proteoform-centric network,
with the proteoforms of the p53 protein numbered in red nodes, and proteo-
forms of other proteins as small green nodes. Red edges indicate interactions
between p53 protein isoforms, green edges interactions between p53 protein
isoforms and isoforms from other proteins. Figure adapted from Additional
Paper I (Hernández Sánchez et al., 2019).
4 Design of proteomics
experiments
When designing a comparative proteomics experiment there are mul-
tiple aspects to take into account. As a general rule, the better the
experiment is planned, the more straightforward the analysis of the
data. The first step is deciding what treatments (or disease states, etc.)
to compare and which other variables are likely to influence the out-
come measurement(s) studied. Next, the type of samples should be
appropriate to answer the research question, and subjects need to be
recruited or cell lines grown. Finally, to be able to answer the research
question, a sufficient number of samples should be available, and the
sample processing order should not introduce confounders (Box et al.,
2005).
4.1 Sample populations
Different research questions require different types of samples to be
answered efficiently. Samples can be taken from a single subject, or from
an environment, e.g. soil samples. The latter consist of multiple species,
so-called metaproteomics, and are outside the scope of this thesis. On
the other end of the spectrum there is single-cell analysis, in which
the proteome of each cell in the sample is analysed separately. This
technique is becoming increasingly popular (e.g. Specht et al., 2021),
though the bulk of proteomics analyses is still done on populations of
cells.
One of the main differences for single subject samples is between
biological samples and cell lines, which are grown in a laboratory. By
applying a treatment to the cells, one can see what happens to the
treated vs. the untreated cell line. If the treatment would do nothing at
all, the treated and untreated cell lines should be the same. Biological
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samples are taken from biological entities, such as humans or other
animals, which differ on more than just the treatment. This biological
variation needs to be taken into account when modelling the effect of
treatments, and is vital for extrapolating to individuals outside the
study.
When using samples from subjects, one of the first questions con-
cerning the design of the experiment is whether to make comparisons
between groups of subjects or comparisons within subjects in different
states. When the interest is in differences between disease states, the
only option is often to recruit subjects who do have the disease and
subjects who do not have the disease. This results in average differ-
ences between subjects in different disease states. In diseases where the
disease manifests itself in only a part of a tissue, as in specific cancers,
it is possible to take a ‘healthy’ and a ‘disease’ sample of the same
tissue type from the same subject. Then, the difference between the
tissues from the same subject should only differ in terms of the disease,
while for the whole population the variation between subjects can still
be modelled.
Similarly, when analysing the effect of a drug, a common strategy
is to perform a cross-over trial or a longitudinal study. In a cross-over
trial, subjects receive two or more treatments at different time points
and one can compare how each subject reacts to both treatments. To
avoid biases, subjects should receive the treatments in a random order
and there should be sufficient time between the treatments.
When interest is in the progression of a disease or the recovery tra-
jectory of subjects, measuring protein abundances at multiple time
points in a longitudinal study can show differences in the trajector-
ies of the subjects. There are generally two ways to approach a lon-
gitudinal study, which is to either process samples as they come in,
or to process all samples together after collecting all samples (Mer-
tens, 2017). The former has the advantage of avoiding storage effects,
but introduces sample processing days or batches as a confounder for
the time-dependent effect studied. However, the latter approach intro-
duces sample storage time as a perfect confounder, in which case care
should be taken that the interest is in proteins that are stable when
stored over longer time periods (Gast et al., 2009; Meier et al., 2020;
Tsuchida et al., 2018; Tworoger and Hankinson, 2006).
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4.2 Power and balance
When the types of samples, the type of analysis, and the research ques-
tion is decided upon, a statistical model should naturally present itself.
This model should account for the research design, and should make
it possible to answer the research question. Once a preliminary model
is chosen, it is advisable to calculate whether the number of available
samples is enough to estimate the parameters of interest with satisfact-
ory precision. Alternatively, the number of samples needed for this can
be calcualted.
The traditional way of calculating the required number of samples is
by performing a power analysis, which is done by calculating the Type
I (false positive) and Type II (false negative) error probabilities based
on pre-specified effect size, variance and sample size (Oberg and Vitek,
2009; Riter et al., 2005). Type I and 1 − Type II error rates are also
called the size and power of a test. However, given the interdepend-
ent nature of protein abundances, the complex models and expected
high prevalence of missing values, and the subsequent multiple testing
correction, it is not always clear how to perform or interpret classical
power analyses in omics settings. While sample size calculations for
omics studies have been proposed (e.g. Müller et al., 2004; Tibshirani,
2006), these all rely either on pilot data or known/expected test statistic
distributions. In a typical discovery study, however, this might not be
available. With potentially limited population sizes, and the high cost
of acquiring and processing samples, the discovery phase of the exper-
iment is often seen as a kind of pilot study for the validation phase.
Expected variances and effect sizes might also be hard to estimate from
related previous studies, when these are done with different protocols,
using different instruments, and/or different software pipelines.
It is therefore easier to perform a power analysis in the validation
phase. Then, one can use the effect size and variance estimates from
the discovery phase to estimate what an appropriate sample size would
be for the proteins/peptides included in the validation phase.
An alternative to power analysis is an evaluation in terms of Type
S (sign) and Type M (magnitude) errors (Gelman and Carlin, 2014).
These give an indication concerning how likely it is that the magnitude
of the effect is far from the true effect size (a Type M error), and how
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likely the true effect is actually in the opposite direction (a Type S
error). For all these statistics concerning the design of the experiment,
i.e. both for power calculations and Type S- and Type M-errors, it is
important to remember that the initial effect size and variance estim-
ates on which these calculations are based should come from realistic
external estimates. Both published literature and the ‘significant’ pro-
teins from the current study are likely to overestimate effect sizes.
The numbers of samples that are recruited can always, for various
reasons, be lower than what was aimed for. Ideally, the number of
subjects recruited is (nearly) balanced in terms of the characteristics
important for the research question, i.e. the variables in the analytical
model. When there are many more samples in one group compared
to another the estimation of group differences can become challenging.
Balance has certain advantages as parameter estimation is optimal (i.e.
has the least variance) when sample sizes are equal, for a given total
sample size.
In general the more samples the better, though there are some not-
able exceptions. Firstly, the larger the sample size, the better paramet-
ers such as the mean or group differences can be estimated. However,
at some point the sample size is large enough that the exact min-
imal meaningful difference between the groups can be observed, and
increasing the sample size(s) after that is a waste of effort and mater-
ials. Similarly, when there is a large imbalance between sample sizes,
adding more samples to the larger group might not meaningfully make
an impact on the power of the test while adding more samples to the
smaller group would.
It might happen that for some groups the number of subjects re-
cruited is much too low. In that case it might make sense to reevaluate
the statistical model and perhaps drop a variable one is less interested
in. Of course, this is only possible if the proposed model still makes
sense without the dropped variable.
4.3 Batching and sample processing order
When the samples are collected, the processing of the samples has to
be prepared. The number of batches and how the treatment groups
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are divided into them should be deliberated in the design phase of the
study. Ideally all samples can be processed as a single batch. When
this is not possible, care should be taken to avoid the introduction of
confounders when dividing samples over batches.
The number of samples that can be processed at once is usually lim-
ited by the time it takes to process one sample and/or limitations of
equipment. As samples generally have to be stored under a strict set of
circumstances, e.g. long term storage at −80◦C, and start to degrade
when defrosted, the number of samples that can be processed after de-
frosting can be limited (Tsuchida et al., 2018; Tworoger and Hankinson,
2006). Similary the number of samples that can be processed on e.g. a
single 96-well plate is limited to 96, and with 10-plex TMT the max-
imum number of samples in one pool is nine or ten, depending on the
inclusion of a shared reference sample. The need for batch processing
is thus commonplace.
A batch is a set of samples that is treated (almost) exactly the same
way. Say one set of samples (Set A) is processed on one day, and another
set of samples (Set B) is processed the next day, these would be two
different batches. When, in addition, both sets of samples are processed
by two different instruments (Instrument 1 and Instrument 2 ), this will
lead to four batches: A1, A2, B1, and B2. However, if all samples of
Set A are processed on one instrument, and all samples of Set B on
the other instrument, there are still only two batches: A1, and B2. The
batch effects introduced by the days of processing and those introduced
by the different instruments are confounded, and thus combined into a
single batch effect. Each type of batch (here instrument and processing
day) has to be added to the analytical model as a factor variable. If
the batch variable is not included in the model, the batch effect would
at best, i.e. when orthogonal to the treatments, increase variances, but
more likely also influence the estimates of the treatment effects.
When creating batches, the main goal is to make each batch like
its own small experiment. Two general rules of thumb can aid in this
process:
1. All batches should be as similar to each other as possible.
2. Each batch should contain as many different treatments as pos-
sible.
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It is easy to make all batches exactly the same when each treatment
has the same number of subjects, the number of subjects per batch
equals the number of treatments, and the number of batches equals the
number of subjects per treatment. In that case each batch contains one
subject of each treatment. Where it is not possible for the batches to be
exactly the same, the similarity of the batches should be seen in terms of
overlap between the treatments represented in each batch. The number
of subjects in each treatment should thus ideally be representative of
their relative frequency in the complete experiment. When the number
of treatments is larger than the batch size, each batch should contain
as many different treatments as possible.
For specific settings, where interest is only in a certain subset of
treatment contrasts, other strategies should be followed. A typical ex-
ample is where two current treatments (Ta and Tb) are compared to a
single new treatment (Tn), and the main goal is to compare the new
treatment to each of the current treatments. Comparisons between the
two current treatments would not change the evaluation of the new
treatment and are consequently not of interest. Batches would then
mainly (or only) combine samples from the new treatment with the
current treatments, rather than combining samples from the current
treatments.
Even with only a single batch one can usually process only one sample
at a time, both in the laboratory and on the instrument that analyses
the samples. This can introduce a time-dependent effect, which means
that one should also consciously decide on a processing order of the
samples. The most appropriate strategy is to use block randomisation
to decide upon the order of the treatments, followed by a random alloca-
tion of subjects to slots according to their treatment (Figure 4.1). While
it is important to minimise time-dependent effects using block random-
isation, run-order effects on LCMS are usually unavoidable, making it
essential to afterwards check the run-order effect. This also underlines
the importance of reference samples, which should be included in each
batch and run at set intervals in the run order (Surowiec et al., 2018).
Further details on block randomisation can be found in Additional Pa-
per II .
While for smaller cohorts and standard and/or balanced settings it
is feasible to find (near-)optimal batch allocations by hand, this can
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quickly become challenging and time-consuming. An automated pro-
cedure for allocating subjects into batches can aid researchers, free-
ing them to concentrate on other aspects of the experiment. Therefore
we devised an algorithm to allocate subjects into batches, based on
the principles stated above, where blocking is based on only a single
variable, and all treatment contrasts are considered equally important.
Further details on the algorithm and its performance can be found in
Paper III .
5 Papers
5.1 Paper I: Interpreting the structure of pathways
To optimally interpret pathway analysis results, it is important to un-
derstand the structure and organisation of the underlying database.
Using network statistics we investigated the evolution of the connectiv-
ity of the Reactome pathway knowledgebase, and described the hier-
archical and interconnected nature of pathways. Taking into account
the structure of the protein network when performing pathway analyses
can make the analysis more specific, but also more complicated.
This is further described in Paper I :
Burger B., Hernández Sánchez L.F., Lereim R.R., Barsnes H., Vaudel
M. Analyzing the structure of pathways and its influence on the in-
terpretation of biomedical proteomics data sets. Journal of Proteome
Research, 2018, 17, 11, 3801–3809.
5.2 Paper II: Detecting small endogenous peptides
In general peptidomic and proteomic workflows, peptides (and single
amino acids) that cannot attract a charge are structurally missed in
the analysis. We performed a proof-of-concept experiment extending
an existing workflow, allowing us to identify single amino acids and
small endogenous peptides in human cerebrospinal fluid, using a basic
mass-based identification approach. Further development of identifica-
tion and quantification strategies for these molecules might provide a
wealth of additional information, and potentially biomarkers for neur-
ological diseases, using isobaric tags and targeting singly charged mo-
lecules.
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This is further described in Paper II :
Burger B.§, Lereim R.R.§, Berven F.S., Barsnes H. Detecting single
amino acids and small peptides by combining isobaric tags and pep-
tidomics. European Journal of Mass Spectrometry (Chichester), 2019,
25, 6, 451–456.
§ These authors contributed equally.
5.3 Paper III: Automated blocking and batching
In biomedical experiments, batches are generally designed by hand,
which becomes cumbersome for challenging cohort set-ups. We have
developed a fast and intuitive heuristic algorithm to generate balanced
allocations of samples to batches, which can be applied to any single-
variable model where the treatment variable is nominal. We show that
this algorithm provides a marked improvement over random allocations
and yields an optimal solution for small cohorts (up to 108 allocation
possibilities).
This is further described in Paper III :
Burger B., Vaudel, M., Barsnes, H. Automated blocking and batch-
ing of biomedical experiments with sequential processing. Unpublished
preliminary results.
6 Additional work
Following is a list of papers describing additional work performed dur-
ing the period when the PhD was carried out, but which are not in-
cluded as part of the thesis.
Additional Paper I :
Hernández Sánchez L.F., Burger B., Horro C., Fabregat A., Johans-
son S., Njølstad P.R., Barsnes H., Hermjakob H., Vaudel M. Pathway-
Matcher: proteoform-centric network construction enables fine-granu-
larity multiomics pathway mapping. Gigascience, 2019, 8, 8, giz088.
Additional Paper II :
Burger B., Vaudel M., Barsnes H. Importance of block randomisation
when designing proteomics experiments. Journal of Proteome Research,
2021, 20, 1, 122–128.

7 Discussion
This thesis mainly focuses on issues concerning the design and analysis
of proteomics experiments. A number of these topics warrant further
discussion. First, additional challenges in performing and interpreting
pathway analysis will be addressed. These challenges unavoidably arise
from the complex biological entities and processes they describe and
from the way the databases are built up and maintained. Next, oppor-
tunities for expanding proteomics experiments beyond single studies
and single laboratories will be discussed. This includes combining mul-
tiple studies in meta-analyses, but also the combination of multiple
omics platforms to create a systems biology perspective of the relevant
differences between populations. Lastly, challenges and opportunities
of multidisciplinary research are covered, with a focus on the need for
clear and tailored communication.
7.1 Limits of pathway analysis
The main challenges of performing pathway analysis and interpreting
the results were already discussed in Chapter 3.2. However, there are
more general challenges to pathway analysis, most notably concerning
the differences between species and the constant growth of the know-
ledge base.
Species- and disease-specific pathways When choosing protein and
pathway databases, the reference database should be aligned with the
species under investigation, e.g. if a study is done in mice, the protein
and pathway database should be specific for mice. Even though mouse
models are often used to study what would happen in humans, there
are differences in proteins, and pathways and processes in mice cannot
directly be mapped to human pathways. This does not mean that mouse
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models are not relevant or important, but the mapping from mouse to
human is a separate step that requires expert knowledge about the
relevant differences (Mohammed et al., 2020).
Similarly, disease-specific pathways are specific for the given disease.
Overlaps with other disease-mechanisms can be very interesting, but as
the pathway analysis algorithms will try to map to anything that is in
the database, the ‘most relevant’ pathways in the database might not
be the most relevant when interest is in a less exhaustively annotated
disease. The disease pathways included in the database should thus be
specific for the disease under consideration, possibly including related
diseases, to avoid drawing erroneous conclusions.
Database curation Manually curated databases update slower, but
the content should be more trustworthy than that in computationally
derived databases. Additionally, there are commercial pathway data-
bases, e.g. Ingenuity Pathway Analysis (Qiagen), which are curated,
but where the curation process is not necessarily known to the user.
In terms of species-specific pathways and reactions, for example, the
Reactome pathway database is curated for human interactions, but
‘inferred from humans’ for all other species (Jassal et al., 2020). Addi-
tionally, some pathways are better annotated than others, and annota-
tions of pathways can differ between databases (Müller et al., 2011).
Part of the differences in levels of annotation between pathways may
lie in sociological biases. Curation efforts seem to be focused mainly on
proteins that are already well annotated, and the proteins they interact
with, biasing knowledge generation towards areas where there already
is extensive annotation (Rolland et al., 2014). It can be hypothesised
that the same is true for resources and efforts directed towards different
diseases (see, e.g., the biology and diease oriented branch of the Human
Proteome Project Aebersold et al., 2013). Thus, a database should be
selected which has the required level of curation relevant to the research
question.
Pathway specificity An additional challenge is that one can only find
those interactions and pathways that are annotated in the database.
Pathway databases are constantly expanding to incorporate new know-
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ledge. Results of different experiments analysed with different (versions
of) databases might not be directly comparable, and reanalysing the
data with a different (newer) version of the database can lead to differ-
ent results. Using an up-to-date version of the database is thus highly
recommended (Wadi et al., 2016).
Ideally all the known proteins and their different proteoforms are
functionally annotated in the pathway database, with all of their known
interactions. However, many proteins and proteoforms are not annot-
ated in pathway databases. Similarly, in the protein inference step,
when it is not possible to uniquely identify proteins from the identi-
fied peptides, protein groups are constructed. These are a collection
of proteins that the peptides can be mapped to. For pathway analysis
these protein groups are usually reduced to a single protein identifier,
dropping the other possible proteins from the analysis. When, for a pro-
teoform, only information at the protein or gene level is available, the
information is mapped back to the more general level by the pathway
database. These generalisations should be transparent for the user, as
they can influence the results and relevance of the pathway analysis.
7.2 Moving beyond a single study
To study the differences in experimental procedures, there have been
several projects where the same samples have been sent to different
laboratories. The variability in these projects comes from different pro-
tocols, researchers, equipment, instruments, and software (Bell et al.,
2009; Collins et al., 2017; Tabb et al., 2010). In multi-centre studies
this variability comes in addition to the biological variability, while a
question for single-centre studies becomes how reproducible the results
are in other laboratories, and with other protocols and instruments.
Due to limitations in the number of available resources, large studies
(e.g. Ellis et al., 2013; Riley et al., 2011) are often not possible. For
example, in studies concerning rare diseases the number of possible
samples to recruit can be very low. However, for wide applicability
there is only so much that can learned from a single experiment.
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Combining independent studies Multiple relevant studies can poten-
tially be combined by performing a meta-analysis and/or systematic
review, even when they have different protocols and/or instruments
and are relatively small themselves. There are many different ways of
performing a meta-analysis, but generally the results from each study
are extracted and a weighted average is calculated, incorporating the
uncertainties from the individual studies. When individual patient in-
formation is available, as is usually the case with proteomics studies in
the form of publicly available raw data files, this can be used instead to
combine different studies (a one-stage approach), or to recalculate study
specific results (a two-stage approach) (Debray et al., 2015). While this
is common practice in drug development (see e.g. cochrane.org), it is
less commonly done in proteomics (e.g. Dupae et al., 2014; Rehiman
et al., 2020; Srisawat et al., 2017).
Combining different omics platforms Another approach is to per-
form multiple omics studies with the same samples, usually done by
splitting each sample into two (or more) and processing each frac-
tion separately for each platform. Different classes of biomolecules can
provide complementary information, increasing the amount of know-
ledge one can gain from a single experiment. Furthermore, proteins are
generated from mRNA, which in turn is transcribed from DNA by pro-
teins. In general, cellular homeostasis depends on an interplay of DNA,
RNA, proteins, and metabolites, thus, for a complete understanding
of cellular processes, ideally the interplay of all biomolecules is stud-
ied (Veenstra, 2021). When sample collection is difficult or expensive,
e.g. when taken during an invasive procedure or when studying rare
diseases, it is especially important to maximise the knowledge gained
from each sample. If different classes of biomolecules can be extracted
from the same sample, without needing drastically more material, a
multi-omics approach could be an option (Blum et al., 2018; Hörmann
et al., 2019).
The study of nucleic acids, i.e. DNA and RNA, generally requires
different technologies compared to the study of amino acids and meta-
bolites. Even though the latter two are both commonly processed by
mass spectrometry, the sample processing and computational analysis
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differ substantially. When both proteins and metabolites are extracted
from the same sample, sample preparation has to be done in a way
that preserves the biological information contained in both classes of
biomolecules (Blum et al., 2018). Many protocols for both proteomics
and metabolomics exist, depending on sample type, object of the ex-
periment, and possible type of proteins and metabolites targeted (e.g.
Lygirou et al., 2014; Micic, 2016; Santamaŕıa and Fernández-Irigoyen,
2019; Walker, 2005). As metabolites, usually including very small pep-
tides, generally have smaller mass than proteins, the sample can be
split based on mass, with both fractions subsequently treated and run
in a metabolomics- and proteomics-specific way. Results can then be
combined by performing pathway analysis based on both protein and
metabolite interactions (Blum et al., 2018; Xu et al., 2020; Zhang et al.,
2018).
7.3 Communication in multidisciplinary research
Proteomics experiments are inherently multidisciplinary endeavours.
First and foremost, there is the biological and biochemical knowledge
concerning the research question and the processing of the samples in
the laboratory and on the instrument. Given the enormous amount
of data that is generated for each sample, bioinformatics methods are
necessary to process the data into a form that can hopefully be used
to answer the research question(s). Appropriate statistical methods are
needed to analyse the resulting data, and the interpretation of the
results falls again in the domain of the biologist. Communication across
these fields is thus essential.
Given that the vocabulary in these fields differ, the concepts that are
basic for one research area might not be so in another field. It is thus
important for researchers to have at least a basic understanding of the
other fields and be able to communicate at a level that is understand-
able across different backgrounds. This can be challenging, and requires
a lot of patience, but gets easier with practice and experience. Estab-
lishing a good working relationship with the researchers in the other
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Hörmann, P., Barkovits, K., Marcus, K., and Hiller, K. (2019). Co-
extraction for metabolomics and proteomics from a single CSF
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